These findings suggest that higher 25(OH)D levels are associated with shorter actigraphic sleep latency in SA, but not when controlling for the confounders of musculoskeletal pain or light exposure. In C, it is unclear why controlling for bone pain leads to the appearance of a relationship between 25(OH)D and sleep latency, and why participants with worse self-reported sleep (using PSQI) have better 25(OH)D status. These results are not easy to interpret, but suggest a potential mediating effect of ethnicity, musculoskeletal pain and light exposure in the relationship between 25(OH)D and both sleep latency and self-reported sleep quality. This interpretation is supported by previous studies showing a link between sleep problems and musculoskeletal pain 3 and the fact that daytime light exposure is important to sleep health. Actigraphy, however, has known limitations in measuring sleep latency, and the number of subjects with valid light data were small. Further research in this area is warranted.
The D-FINES II study was supported by a PhD studentship for ALD from the University of Surrey. *n = number of subjects with both valid actigraphic activity data for ⩾ 7 days and 25(OH)D **n = number of subjects with both valid a PSQI score and 25(OH)D. ±Time taken to fall asleep, ¥ % of time in bed that subject asleep. ≠Overall sleep quality, higher score = poorer sleep ∞ higher score = longer time duration.
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